Long-lasting control with erlotinib in advanced non-small cell lung cancer (NSCLC).

The authors present a clinical case of a caucasian male patient, 59 years-old, non-smoker, with an advanced non-small cell lung carcinoma (NSCLC), with 3 years of follow-up, received erlotinib for 18 months, after failure of more than one chemotherapy schedule, without evidence of oncologic progression. The patient evidences excellent quality of life, controlled sintomatology, recovery of the capacity of tolerance to the effort and it maintains his professional activities. The treatment with erlotinib has been well tolerated, although exhibiting grade 1 cutaneous toxicity.

Validation of the Portuguese version of the Asthma Quality of Life Questionnaire [AQLQ-M] by Marks.

Quality of Life is one of the leading evaluations in the diagnosis, therapy and investigation of patients with asthma. The aim of this study was to evaluate the psychometric properties of the Portuguese version of the Asthma Quality of Life Questionnaire (AQLQ-M) designed by Marks in Australia. This questionnaire consists of 20 items describing the impact of asthma on patient's lifestyle and covers 4 dimensions (breathlessness, mood, social limitation and worrying).